Clinical Trials Using Fostamatinib Disodium
Clinical trials are research studies that involve people. The clinical trials on this list are studying Fostamatinib Disodium. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Location: 2 locations
Fostamatinib Disodium and Paclitaxel in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of fostamatinib disodium when given together with paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Fostamatinib disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving fostamatinib disodium together with paclitaxel may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland
Fostamatinib Alone or in Combination with Ruxolitinib for Treatment of Patients with Intermediate- or High-Risk Myelofibrosis with Severe Thrombocytopenia
This phase II trial studies the effects of fostamatinib alone or in combination with ruxolitinib in treating patients with intermediate- or high-risk myelofibrosis with severe thrombocytopenia (low platelet count). Fostamatinib may help treat severe thrombocytopenia by blocking a certain enzyme. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving fostamatinib in combination with ruxolitinib may work better in treating myelofibrosis.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Fostamatinib Disodium in Preventing Chronic Graft Versus Host Disease in Patients with Hematologic Malignancies after Donor Stem Cell Transplant
This phase I trial studies the side effects and best dose of fostamatinib disodium in preventing chronic graft-versus-host disease in patients with hematologic malignancies after donor stem cell transplant. Chronic graft-versus-host disease is a common complication of a donor stem cell transplant, usually occurring more than three months after transplant, in which donor lymphoid cells damage the host tissue. Fostamatinib disodium may prevent the development of chronic graft-versus-host disease in patients after a donor stem cell transplant.
Location: Duke University Medical Center, Durham, North Carolina